Improved overall survival after contralateral risk-reducing mastectomy in brca1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis
Improved overall survival after contralateral risk-reducing mastectomy in brca1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis
复制标题
DOI：
10.1002/ijc.29032
复制
发表时间：
2015-02-15
影响因子：
6.4
通讯作者：
Seynaeve, Caroline
中科院分区：
文献类型：
--
作者：
Heemskerk-Gerritsen, Bernadette A. M.;Rookus, Matti A.;Seynaeve, Caroline
BRCA1/2相关的原发乳腺癌(PBC)患者选择随后的对侧降低风险乳房切除术(CRRM)的生存数据很少，而且不一致。我们研究了CRRM对有PBC病史的突变携带者的总存活率的影响。从一个荷兰多中心队列中，我们选择了583名BRCA相关的PBC患者，他们在1980至2011年间被诊断出来。随着时间的推移，242名患者(42%)接受了CRRM，341名患者(58%)仍在接受监测。生存分析使用COX模型，CRRM作为时间依赖协变量。诊断为PBC后的中位随访期为11.4年。CRRM组有4例患者患对侧乳腺癌(2%)，而监测组患者(19%)发生对侧乳腺癌(P<0.05)。
Data on survival of BRCA1/2-associated primary breast cancer (PBC) patients who opt for subsequent contralateral risk-reducing mastectomy (CRRM) are scarce and inconsistent. We examined the efficacy of CRRM on overall survival in mutation carriers with a history of PBC. From a Dutch multicentre cohort, we selected 583 BRCA-associated PBC patients, being diagnosed between 1980 and 2011. Over time, 242 patients (42%) underwent CRRM and 341 patients (58%) remained under surveillance. Survival analyses were performed using Cox models, with CRRM as a time-dependent covariate. The median follow-up after PBC diagnosis was 11.4 years. In the CRRM group, four patients developed contralateral breast cancer (2%), against 64 patients (19%) in the surveillance group (p